Drug development and the FDA's Critical Path Initiative

Area of Science:

• Biomedical Research
• Pharmaceutical Sciences
• Drug Development

Background:

• Recent decades have seen substantial advances in biomedical research, increasing expectations for new drug therapies.
• However, the pharmaceutical industry faces significant limitations in translating this research into successfully marketed therapies.
• These limitations pose a risk to the effective delivery of new treatments to patients.

Purpose of the Study:

• To highlight the challenges in translating biomedical research into new therapies.
• To inform clinical pharmacologists about the signals indicating limitations in drug development.
• To propose a strategy where clinical pharmacology can improve the drug development process.

Main Methods:

• Review of current trends in biomedical research and pharmaceutical development.
• Analysis of identified limitations in the drug translation pipeline.
• Discussion of strategic roles for clinical pharmacology in drug development.

Main Results:

• Biomedical research progress has not consistently translated into a proportional increase in marketed therapies.
• Specific limitations within the drug development process hinder the effective translation of research findings.
• Clinical pharmacology possesses the potential to address and mitigate these developmental hurdles.

Conclusions:

• The pharmaceutical industry's ability to translate biomedical research into new therapies is facing serious limitations.
• Clinical pharmacologists must be aware of these challenges and their implications.
• Implementing a strategic role for clinical pharmacology is crucial for improving drug development efficiency and success rates.